HC Wainwright Issues Positive Outlook for ATRA Earnings

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Equities research analysts at HC Wainwright increased their Q2 2025 earnings estimates for Atara Biotherapeutics in a note issued to investors on Tuesday, January 28th. HC Wainwright analyst R. Burns now anticipates that the biotechnology company will post earnings per share of ($4.04) for the quarter, up from their previous forecast of ($4.15). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Atara Biotherapeutics’ current full-year earnings is ($9.86) per share. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q4 2025 earnings at ($3.59) EPS and FY2025 earnings at ($8.41) EPS.

Other research analysts have also issued reports about the stock. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Canaccord Genuity Group dropped their price target on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, January 17th. Rodman & Renshaw started coverage on shares of Atara Biotherapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, RODMAN&RENSHAW lowered Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Stock Performance

Shares of Atara Biotherapeutics stock opened at $8.49 on Thursday. The stock has a market cap of $48.90 million, a price-to-earnings ratio of -0.33 and a beta of 0.51. The stock has a 50 day moving average price of $11.74 and a 200-day moving average price of $9.92. Atara Biotherapeutics has a one year low of $5.40 and a one year high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to the consensus estimate of $23.00 million. During the same period in the previous year, the firm earned ($16.50) earnings per share.

Institutional Investors Weigh In On Atara Biotherapeutics

Several large investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Atara Biotherapeutics during the second quarter valued at approximately $53,000. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics during the 2nd quarter valued at $79,000. State Street Corp lifted its holdings in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after buying an additional 7,680 shares during the period. FMR LLC grew its position in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 4,043 shares during the period. 70.90% of the stock is owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.